Utilization and safety of digoxin in patients with chronic heart failure and atrial fibrillation with rapid ventricular rate

30 August 2024 (12:00 - 12:50)

Organised by:

Video

Sign in for access options

Abstract

Slides

About the speaker

Doctor Kristian Berge

Akershus University Hospital - AHUS, Nordbyhagen (Norway)

8 More presentations in this session

Presentation thumbnail

Effects of Sacubitril/Valsartan on all-cause hospitalizations in heart failure: participant-level pooled analysis of PARADIGM-HF and PARAGON-HF

Doctor H. Lu (Lausanne, CH)

Abstract Slides Video

Presentation thumbnail

Tafamidis treatment for transthyretin amyloid cardiomyopathy: results from an open-label, early-access, long-term study extension in an all-comers population

Professor M. Crespo-Leiro (A Coruna, ES)

Abstract Slides Video

Presentation thumbnail

Efficacy of sotagliflozin by diabetes duration: a secondary analysis of SCORED

Doctor R. Aggarwal (Boston, US)

Abstract Slides Video

Presentation thumbnail

Effects of dapagliflozin in heart failure according to duration of type 2 diabetes: a patient-level meta-analysis of DAPA-HF and DELIVER

Doctor J. Butt (Copenhagen, DK)

Abstract Slides Video

Presentation thumbnail

Long-term follow-up of the TRED-HF trial

Miss L. Cheng (London, GB)

Abstract Slides Video

Access the full session

Session thumbnail

Drug therapy for heart failure: what is new?

The Event

Event poster

ESC Congress 2024

30 August 2024 12:00 CET

You may be interested in

Congress Presentation

Efficacy and safety of digitoxin in heart failure with reduced ejection fraction according to atrial fibrillation: Insights from DIGIT-HF

Congress Session

Hottest trials (2)

Congress Presentation

DIG-META: Digoxin in heart failure and atrial fibrillation

ESC 365 is supported by

novartis

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources